Thymalin
Evidence: CAnti-inflammatory / gut / skin research
Evidence Snapshot
What this grade covers
B for broad product identity as a thymic polypeptide extract; C/D for limited older human and preclinical evidence; E for established efficacy, safety, longevity, immune restoration, FDA approval, or dosing.
Regulatory Context
No FDA-approved Thymalin product was identified. Thymalin should not be conflated with thymulin, thymosin alpha-1, thymosin beta-4, Thymogen, or other thymic peptides.
Research Takeaway
Thymalin is a polypeptide preparation historically obtained from animal thymus rather than a single chemically defined short peptide; it must be distinguished from thymosin alpha-1/thymalfasin, thymosin beta-4, TB-500, thymulin, thymopentin, Thymogen, Crystagen, and Vilon.
Evidence boundary: Findings for a defined synthetic thymic peptide cannot automatically be assigned to a heterogeneous thymic extract preparation.
See all 6 evidence claims →Quick Summary
Thymalin is described in the literature as a polypeptide extract or complex isolated from calf thymus, not a single defined peptide sequence. Cell studies and several small or observational human reports exist, but product composition, study quality, and independent replication limit confidence.
Mechanism & Research Overview
Thymalin is proposed to influence immune-cell differentiation and cytokine signaling through multiple small peptides within a thymus-derived extract. Because it is a mixture, results cannot automatically be assigned to one peptide or generalized to other thymic products.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Thymalin is a polypeptide preparation historically obtained from animal thymus rather than a single chemically defined short peptide; it must be distinguished from thymosin alpha-1/thymalfasin, thymosin beta-4, TB-500, thymulin, thymopentin, Thymogen, Crystagen, and Vilon.
Does not establish
Evidence boundary: Findings for a defined synthetic thymic peptide cannot automatically be assigned to a heterogeneous thymic extract preparation.
Supported
Historical human studies reported immunologic or clinical effects of Thymalin in specific conditions, including pediatric herpetic stomatitis and chronic active hepatitis.
Does not establish
Evidence boundary: These older studies are limited by reporting era, design details, replication, and modern standards of evidence.
Supported
Long-term gerontology publications have reported survival or aging-related outcomes in programs using thymic and pineal peptide preparations including Thymalin.
Does not establish
Evidence boundary: These reports should not be presented as proof that Thymalin extends human lifespan because independent replication and modern trial methodology are insufficient.
Sources: Peptides of pineal gland and thymus prolong human life
Supported
The composition and standardization of a thymus-derived polypeptide preparation are central evidence limitations: historical Thymalin findings cannot be assumed to apply to every contemporary product sold under the same name.
Does not establish
Evidence boundary: Product-name continuity is not proof of molecular equivalence.
Supported
The verified literature is insufficient to define a modern, route-specific, dose-specific long-term safety profile for currently marketed Thymalin preparations.
Does not establish
Evidence boundary: Historical clinical use does not replace contemporary product characterization, pharmacovigilance, or controlled safety assessment.
Supported
Thymalin should remain presented as a historically studied thymic polypeptide preparation with limited modern clinical validation, not as an interchangeable form of thymosin alpha-1 or an established anti-aging therapy.
Does not establish
Evidence boundary: Evidence grade C recognizes human literature while preserving its major methodological and product-identity limitations.
Sources: Peptides of pineal gland and thymus prolong human life
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Thymalin is an incompletely standardized animal-tissue-derived polypeptide complex, so composition and impurity risks depend on manufacturing.Safety Consideration
Human reports are small, old, adjunctive, observational, or otherwise vulnerable to bias and confounding.Safety Consideration
Immune modulation may be clinically significant in infection, autoimmunity, transplant, and cancer contexts, but route-specific safety data are inadequate.Safety Consideration
Evidence for one Thymalin preparation cannot be generalized to all products sold under the name.Safety Consideration
Important concerns include animal-derived biological starting material; batch-to-batch peptide-composition variability; incomplete molecular characterization; source-animal and manufacturing controls; contamination, adventitious-agent, sterility, and endotoxin risks; hypersensitivity and immunogenicity; immune overstimulation, suppression, or autoimmune effects; interactions with vaccines, immunosuppressants, transplant drugs, cancer therapy, and infection treatment; unknown hepatic, renal, hematologic, cardiovascular, neurologic, reproductive, pregnancy, and pediatric effects; and inadequate long-term repeated-course safety and modern pharmacovigilance data. Historical use and claims of low toxicity do not replace controlled safety evidence.
Research Areas Being Studied
Research areas discussed on this page reflect the Anti-inflammatory / gut / skin research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Peptide drug Thymalin regulates immune status in severe COVID-19 older patients (2021):
- Peptides of pineal gland and thymus prolong human life (2003):
- Geroprotective effect of Thymalin and Epithalamin (2002):
- Thymalin as an adjunct in therapeutically resistant psychiatric patients with immune abnormalities (1990):
- Thymalin as Adjunctive Therapy in Pulmonary Tuberculosis ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Peptide drug Thymalin regulates immune status in severe COVID-19 older patients | 2021 | Older hospitalized patients with severe COVID-19 receiving complex therapy | The report described immune-marker and clinical observations in patients receiving Thymalin as an adjunct to standard treatment. | Small, context-specific study with concomitant treatments; not sufficient to establish efficacy for COVID-19 or other indications. | |
| Peptides of pineal gland and thymus prolong human life | 2003 | Long-term observations in older adults receiving thymic and pineal peptide preparations | The publication reports survival associations after treatment with Thymalin and Epithalamin. | Non-randomized, likely overlapping cohorts and products; causal longevity claims are not established. | |
| Geroprotective effect of Thymalin and Epithalamin | 2002 | Older adults followed after courses of Thymalin and/or Epithalamin | The article reports lower mortality and fewer respiratory illnesses in treated groups over long follow-up. | Older, non-randomized, combination-treatment report with substantial confounding and limited modern methodological detail. | |
| Thymalin as an adjunct in therapeutically resistant psychiatric patients with immune abnormalities | 1990 | 36 psychiatric patients with immune abnormalities | The older report describes Thymalin used with other treatment and changes in selected clinical and immune measures. | Small adjunctive study with obsolete standards and limited safety reporting. | |
| Thymalin as Adjunctive Therapy in Pulmonary Tuberculosis | An older comparative study evaluated Thymalin as an adjunct to standard therapy in pulmonary tuberculosis. Study age, reporting limitations, combination treatment, and changes in modern standard care mean this does not establish independent antimicrobial efficacy or justify replacement of established treatment. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The influence of KE and EW dipeptides in the composition of Thymalin on gene expression and cytokine synthesis | 2023 | Cell-based analysis of a thymus polypeptide extract and proposed active dipeptides | The paper defines Thymalin as a thymus-derived polypeptide extract and investigates KE and EW dipeptides as proposed active components. | Composition and activity of a branded extract may vary by manufacturing process; this is not evidence for a single defined peptide. | |
| Thymalin: activation of differentiation of human hematopoietic stem cells | 2020 | Human hematopoietic stem cells in culture | Thymalin exposure was associated with changes in markers related to immune-cell differentiation. | In vitro evidence; does not establish clinical immune restoration. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| 503A Bulk Drug Substances Categories, Updated May 14, 2026 | 2026 | Thymalin was not identified on the reviewed current FDA 503A or 503B bulk-substance category lists or FDA peptide safety table; Cibinetide (ARA-290) is listed in Category 3, meaning it was nominated without adequate support for FDA evaluation. Absence from those lists, or Category 3 status, is not approval, a safety determination, or authorization to compound, and Category 3 is not the Category 1 pathway under which FDA described interim enforcement discretion. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The use of Thymalin for immunocorrection and molecular aspects of its activity | 2021 | Narrative review of thymic peptides and short bioregulators | The review discusses Crystagen in immune and stress-resistance contexts and provides related identity context. | Secondary source; product-specific evidence is sparse and independent replication was not verified. | |
| Natural and synthetic thymic peptides as therapeutics for immune dysfunction | 1997 | Review of thymic peptide preparations | The review discusses Thymalin, Thymogen, and other thymic preparations as distinct products. | Secondary source; should not be used to merge Thymalin with thymulin, thymosins, or defined synthetic peptides. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for Thymalin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.